Inhaled Insulins
Overview
Authors
Affiliations
As a result of knowledge gained from the management of asthma with inhalers and nebulisers, pulmonary delivery devices for insulin have been developed. Particle size of the aerosol particularly influences drug delivery. Although several pharmaceutical companies are developing different systems, Pfizer have launched the first inhaled insulin (Exubera). Clinical trials have taken place in patients with both type 1 and type 2 diabetes, but have shown similar glucose control as subcutaneous insulin delivery. However, patient satisfaction does seem to be increased in patients taking inhaled insulins. Further studies are needed to investigate compliance, side-effect profiles, quality of life, long-term glycaemia control and cost effectiveness.
The Discovery of Insulin: An Important Milestone in the History of Medicine.
Vecchio I, Tornali C, Bragazzi N, Martini M Front Endocrinol (Lausanne). 2018; 9:613.
PMID: 30405529 PMC: 6205949. DOI: 10.3389/fendo.2018.00613.
Technosphere insulin: defining the role of Technosphere particles at the cellular level.
Angelo R, Rousseau K, Grant M, Leone-Bay A, Richardson P J Diabetes Sci Technol. 2010; 3(3):545-54.
PMID: 20144294 PMC: 2769873. DOI: 10.1177/193229680900300320.
Pharmaceutical particle engineering via spray drying.
Vehring R Pharm Res. 2007; 25(5):999-1022.
PMID: 18040761 PMC: 2292490. DOI: 10.1007/s11095-007-9475-1.